Hiteck(SZ:300683) Ge Long Hui A P P·2025-12-30 13:15Core Viewpoint - Hite Bio (300683.SZ) has approved changes to the use of part of its raised funds, including the completion of the "Phase I Project of High-end API Production Base (API&CDMO)" and reallocating surplus funds to permanently supplement working capital [1] Group 1 - The company has decided to conclude the "Phase I Project of High-end API Production Base (API&CDMO)" and will use the surplus funds for working capital [1] - The investment project "High-end API R&D Pilot Project" will be changed to "Research Project for New Indications of National Class I New Drug Epanutuzumab" [1] - The implementation entity for the project will be changed from "Hanrui Pharmaceutical (Jingmen) Co., Ltd." to "Wuhan Hite Bio Pharmaceutical Co., Ltd." [1]